A detailed history of Tiedemann Advisors, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Tiedemann Advisors, LLC holds 3,909 shares of BMY stock, worth $230,122. This represents 0.01% of its overall portfolio holdings.

Number of Shares
3,909
Previous 3,979 1.76%
Holding current value
$230,122
Previous $254,000 11.02%
% of portfolio
0.01%
Previous 0.01%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$57.89 - $64.73 $4,052 - $4,531
-70 Reduced 1.76%
3,909 $226,000
Q2 2023

Jul 20, 2023

SELL
$63.71 - $70.74 $101,872 - $113,113
-1,599 Reduced 28.67%
3,979 $254,000
Q1 2023

Apr 26, 2023

BUY
$65.71 - $74.53 $72,281 - $81,983
1,100 Added 24.56%
5,578 $386,000
Q4 2022

Feb 08, 2023

BUY
$68.48 - $81.09 $10,614 - $12,568
155 Added 3.59%
4,478 $322,000
Q3 2022

Oct 28, 2022

BUY
$0.13 - $76.84 $84 - $50,176
653 Added 17.79%
4,323 $308,000
Q2 2022

Aug 03, 2022

SELL
$72.62 - $79.98 $26,506 - $29,192
-365 Reduced 9.05%
3,670 $285,000
Q1 2022

Apr 27, 2022

BUY
$61.48 - $73.72 $19,858 - $23,811
323 Added 8.7%
4,035 $298,000
Q4 2021

Feb 09, 2022

SELL
$53.63 - $62.52 $111,711 - $130,229
-2,083 Reduced 35.94%
3,712 $230,000
Q3 2021

Nov 12, 2021

SELL
$59.17 - $69.31 $211,000 - $247,159
-3,566 Reduced 38.09%
5,795 $347,000
Q2 2021

Aug 12, 2021

SELL
$61.91 - $67.42 $23,711 - $25,821
-383 Reduced 3.93%
9,361 $626,000
Q1 2021

May 13, 2021

BUY
$59.34 - $66.74 $28,779 - $32,368
485 Added 5.24%
9,744 $619,000
Q4 2020

Feb 16, 2021

BUY
$57.74 - $65.43 $12,009 - $13,609
208 Added 2.3%
9,259 $579,000
Q3 2020

Nov 12, 2020

SELL
$57.43 - $63.64 $17,745 - $19,664
-309 Reduced 3.3%
9,051 $544,000
Q2 2020

Nov 12, 2020

BUY
$54.82 - $64.09 $286,763 - $335,254
5,231 Added 126.69%
9,360 $553,000
Q2 2020

Aug 05, 2020

SELL
$54.82 - $64.09 $281,884 - $329,550
-5,142 Reduced 55.46%
4,129 $244,000
Q1 2020

May 07, 2020

SELL
$46.4 - $67.43 $1,299 - $1,888
-28 Reduced 0.3%
9,271 $517,000
Q4 2019

Feb 12, 2020

BUY
$49.21 - $64.19 $47,586 - $62,071
967 Added 11.61%
9,299 $597,000
Q3 2019

Nov 06, 2019

SELL
$42.77 - $50.71 $9,537 - $11,308
-223 Reduced 2.61%
8,332 $424,000
Q2 2019

Aug 13, 2019

SELL
$44.62 - $49.34 $531,915 - $588,182
-11,921 Reduced 58.22%
8,555 $388,000
Q1 2019

May 13, 2019

SELL
$45.12 - $53.8 $76,162 - $90,814
-1,688 Reduced 7.62%
20,476 $976,000
Q4 2018

Feb 13, 2019

BUY
$48.76 - $63.23 $163,346 - $211,820
3,350 Added 17.81%
22,164 $1.15 Million
Q3 2018

Nov 13, 2018

BUY
$55.19 - $62.25 $217,448 - $245,265
3,940 Added 26.49%
18,814 $1.17 Million
Q2 2018

Aug 14, 2018

SELL
$50.53 - $62.98 $374,477 - $466,744
-7,411 Reduced 33.26%
14,874 $823,000
Q1 2018

May 11, 2018

BUY
$59.92 - $68.98 $995,870 - $1.15 Million
16,620 Added 293.38%
22,285 $1.41 Million
Q4 2017

Feb 14, 2018

SELL
$59.94 - $65.35 $218,840 - $238,592
-3,651 Reduced 39.19%
5,665 $347,000
Q3 2017

Nov 28, 2017

SELL
$55.23 - $63.74 $1.63 Million - $1.88 Million
-29,451 Reduced 75.97%
9,316 $549,000
Q3 2017

Nov 13, 2017

BUY
$55.23 - $63.74 $220,975 - $255,023
4,001 Added 11.51%
38,767 $1.78 Million
Q2 2017

Aug 14, 2017

BUY
N/A
34,766
34,766 $1.92 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Tiedemann Advisors, LLC Portfolio

Follow Tiedemann Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tiedemann Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tiedemann Advisors, LLC with notifications on news.